 DUBLIN, Ohio--BUSINESS WIRE--Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the U.S. Food and Drug Administration FDA has granted the Companys request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis RA and advancement to the pivotal Phase 3 trial. The meeting will take place on Septembe 